APR 26, 2016 9:39 AM PDT

Pancreatic Tumors Spurred On By Cell Death

WRITTEN BY: Xuan Pham
Human PDAC tumors shows co-expression of CXCL1 (red) and CK19 (green; a marker of PADC) by confocal microscopy.Cancer cells may actually be spurred on by the death of nearby cells, reported scientists at the NYU Langone Medical Center. In a bizarre and paradoxical twist, they found that cancer cells thrive on chemical signals released by cells undergoing an orchestrated death event known as necroptosis. Knowing this highlights the importance of studying cancer in the context of its biological system, and could point researchers to new anti-cancer targets.
 
The cells in our bodies are equipped to die when they’re too old or have acquired to many damages or mutations. This biological “self-destruct” mechanism prevents mutated cells from propagating and harming the host. In contrast to the orderly process of programmed cell death induced by apoptosis, cells that die via necrosis experience a messier fate whereby their contents spill into the surrounding environment. This can trigger inflammatory responses that are otherwise absent in apoptosis. Cells can also undergo programmed necrosis – a process known as necroptosis.
 
Despite these checkpoints, cancer notoriously evades cell death, proliferating despite its many mutations. And it may do so by taking in chemical signals from its dead neighbors.
 
The research team, led by George Miller at the NYU Langone Medical Center, focused on pancreatic ductal adenocarcinoma (PDAC) – the most aggressive form of pancreatic cancer to diagnose and treat.
 
They found that dying tumor cells release small proteins called CXCL1, which attract and trap immune cells to prevent them from destroying the cancer cells. The PDAC tumor cells, in turn, use CXCL1 to drive its own tumor growth.
 
"Our findings are the first to show that cancer cell death via necroptosis can actually promote tumor growth, as this process results in suppression of the body's immune response against the cancer," said George Miller, associate professor in the Departments of Surgery and Cell Biology, and senior study author. "What is equally significant is that these findings might also be relevant to other tumor types."
 
In addition to CXCL1, they also found that dying tumor cells also release another protein, SAP130, which activates inflammatory immune cells. They found this activation spurred PDAC tumor growth in mice.
 
"This study exemplifies the importance of examining cancer within the actual context in which it grows," said Gregor Werba, co-first author of the study. "In our initial studies, inhibiting necroptosis in PDAC cells increased their ability to grow in tissue culture. However, when we began to study the same process in mice, we were surprised to see just the opposite effect, and this was mainly due to the immune response of the cells surrounding the tumor." Thus, the team is hopeful to discover new targets for inhibiting cancer growth in the necroptosis pathway. 
 

 Additional source: Science Daily
About the Author
  • I am a human geneticist, passionate about telling stories to make science more engaging and approachable. Find more of my writing at the Hopkins BioMedical Odyssey blog and at TheGeneTwist.com.
You May Also Like
NOV 20, 2019
Clinical & Molecular DX
NOV 20, 2019
New diagnostic technology seeks out cancer DNA in blood
For many cancers, early detection has a tremendous impact on patient outcomes. Yet, sadly, many of the most common malignancies, like those of the stomach,...
NOV 21, 2019
Cancer
NOV 21, 2019
Inhalable nanoparticle-immunotherapy provides new hope for lung cancer
New research published in Nature Communications details the results of a study that tested inhalable nanoparticle-immunotherapy to determine its impact on ...
DEC 18, 2019
Drug Discovery & Development
DEC 18, 2019
A tool that simplifies the hunt for cancer drugs
Cells have long been the internal hubs for proteins that hold a wide variety of unique functions. Disorders on how a cell synthesizes a protein can affect ...
JAN 18, 2020
Cancer
JAN 18, 2020
What's the deal with turmeric?
Have you fallen for the turmeric craze? That little orange root that yellows your fingers when you peel it has become very popular recently for its medicin...
JAN 22, 2020
Cancer
JAN 22, 2020
How the VISTA molecule affects immune responses
A new study describes how a molecule named VISTA has been impeding immune responses in cancer therapies. By turning this molecule “off,” resear...
FEB 15, 2020
Cancer
FEB 15, 2020
New AI tool makes cancer data more efficient
Cancer is everywhere and yet it seems that the more we know about it, the more we have to learn. With almost one and every two people expected to receive a...
Loading Comments...